Assessing Pain by the painDETECT Questionnaire (PDQ)

University Hospital Bispebjerg and Frederiksberg

Status: Active, not recruiting

Conditions: Spondylarthropathies; Inflammatory Arthritis; Psoriatic Arthritis; Rheumatoid Arthritis

Treatments: Drug: bDMARDS

Study type: Observational

Funder types: Other

Identifiers

NCT06402396

DANBIO PDQ

Details and patient eligibility

About

Prospective cohort study using drug survival rates to assess the predictive value of the PDQ when used to classify patients into a non-neuropathic pain phenotype group (score <13) or a neuropathic pain phenotype group (score ≥13)

Full description

The original painDETECT questionnaire (PDQ) DANBIO study was a survey among all DANBIO users having an arthritis diagnosis 'Pain and pain mechanisms in patients with inflammatory arthritis: A Danish nationwide cross-sectional DANBIO registry survey'. The PDQ was implemented onto the DANBIO touch screens for a period of 6 months in 2013-14 and data from more than 7000 individual patients were collected. The overall background for the study was that central pain mechanisms may be prominent in subsets of patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and other spondyloarthritis (SpA). The study showed that approximately 50 % of patients experienced significant pain levels and that a high PDQ score was associated with higher levels of pain and DAS28 but not with markers of inflammatory activity such as CRP and swollen joint count. Furthermore, indications of more frequent bio-switch in the PDQ groups showing neuropathic pain features were found.

The aim of this study is to examine the association between drug retention of biological DMARDs (bDMARDs) and the PDQ pain classification categories (i.e. non-neuropathic vs. neuropathic features) and to investigate whether this categorization is predictive of drug retention and changes in clinical outcomes over a 5-year period.

Enrollment: 7,056 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Registered in DANBIO
• Having inflammatory arthritis (Specific diagnoses include RA, PsA and other SpA)
• At time of the PDQ assessment and up to 4 months thereafter being on ongoing bDMARDs treatment or on switch of bDMARD treatment.

Exclusion criteria

• Missing answer to PDQ

Trial design

7,056 participants in 2 patient groups

Non-Neuropathic pain phenotype

Description:

Based on the PainDETECT Questionnaire (PDQ), patients scoring \<13 will be classified as "exposed" as they are considered a group with non-neuropathic pain (Non-neuropathic pain phenotype)

Treatment:

Drug: bDMARDS

Neuropathic pain phenotype

Description:

Based on the PainDETECT Questionnaire (PDQ), patients scoring ≥13 will be classified as "un-exposed" as they are considered a group with neuropathic pain (neuropathic pain phenotype)

Treatment:

Drug: bDMARDS